Company: CMND
Filing Date: 2025-09-17
Form Type: 6-K
Source: 0001213900-25-088566
Chunk: 1

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-17
Form: 6-K
Chunk 1
---
 as for potential acquisitions to support
its exploration of strategic opportunities.

Notwithstanding the foregoing,
if at any time after the Second Initial Closing, the daily trading volume of the Company’s common shares, no par value per share
(the “Common Shares”), is at least 150% of the amount of Common Shares then outstanding, then the Company may request, at
its sole discretion, that the Holders purchase additional Notes for a purchase price payable in cash equal to 90% of the principal amount,
provided however that the aggregate principal amount of Notes purchased pursuant to the SPAs shall not exceed $7,500,000 during the period
commencing as of the Second Initial Closing and until the date that is three months after the Second Initial Closing, and thereafter shall
not exceed $2,500,000 during each subsequent three-month period, and provided further that the aggregate principal amount of all Notes
purchased pursuant to the SPAs shall not exceed the Subscription Amount.

Each Note will be issued at
a purchase price equal to 90% of the principal amount of such Note, and is to be repaid, together with the accrued due interest, in ten
equal monthly installments beginning on the eighteenth month anniversary of its issuance date, unless repaid earlier (partially or in
full) at the option of the Company or if extended at the option of the Holder. The principal amount under each Note will bear an annual
interest rate of 4% (which will increase to 14% upon an Event of Default, as defined in the Note). The outstanding amount due under each
Note is convertible into the Common Shares at the option of the Holder, at any time after the issuance date of such Note, at a conversion
price equal to the lower of (i) $1.01 and (ii) 12% of the lowest daily volume weighted average price during the 20 consecutive trading
days immediately preceding the applicable date of conversion (the “Variable Price”), provided that such Variable Price may
not be lower than the floor price of $0.20 per Common Share, which is equal to 20% of the VWAP of the Common Shares during the 20 consecutive
trading days immediately prior to the Initial Closing, subject to certain adjustments as provided in the Note. The Holders’ option
to convert the outstanding amount due is subject to the limitation that the conversion may not result in the Holders’ beneficial
ownership exceeding 4.99% of the outstanding Common Shares.

The Company is